ATE474915T1 - Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen - Google Patents

Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen

Info

Publication number
ATE474915T1
ATE474915T1 AT04811794T AT04811794T ATE474915T1 AT E474915 T1 ATE474915 T1 AT E474915T1 AT 04811794 T AT04811794 T AT 04811794T AT 04811794 T AT04811794 T AT 04811794T AT E474915 T1 ATE474915 T1 AT E474915T1
Authority
AT
Austria
Prior art keywords
cell
memory
cells
terminal differentiation
inducing development
Prior art date
Application number
AT04811794T
Other languages
English (en)
Inventor
Warren Leonard
Peter Lipski
Herbert Morse
Catherine Ettinger
Rosanne Spolski
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE474915T1 publication Critical patent/ATE474915T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5052—Cells of the immune system involving B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4612—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/46444—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
AT04811794T 2003-11-19 2004-11-18 Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen ATE474915T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52375403P 2003-11-19 2003-11-19
PCT/US2004/039135 WO2005052139A2 (en) 2003-11-19 2004-11-18 Method of inducing memory b cell development and terminal differentiation

Publications (1)

Publication Number Publication Date
ATE474915T1 true ATE474915T1 (de) 2010-08-15

Family

ID=34632821

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04811794T ATE474915T1 (de) 2003-11-19 2004-11-18 Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen

Country Status (7)

Country Link
US (3) US7993919B2 (de)
EP (1) EP1692276B1 (de)
AT (1) ATE474915T1 (de)
DE (1) DE602004028280D1 (de)
DK (1) DK1692276T3 (de)
GB (1) GB2422845B (de)
WO (1) WO2005052139A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
GB2422845B (en) 2003-11-19 2007-08-01 Us Gov Health & Human Serv Method of inducing memory B cell development and terminal differentiation
US8034326B2 (en) 2005-04-18 2011-10-11 Novo Nordisk A/S IL-21 variants
WO2007031550A2 (en) * 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007057648A1 (en) * 2005-11-18 2007-05-24 Medical Research Council Inhibitors of bcl-6
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
EA031202B1 (ru) 2006-06-06 2018-11-30 Янссен Вэксинс Энд Превеншн Б.В. Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение
EP2091968A2 (de) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21-varianten
EP2109620B1 (de) 2006-12-21 2012-08-22 Novo Nordisk A/S Interleukin-21-varianten mit geänderter bindung an den il-21-rezeptor
US20090175838A1 (en) * 2007-01-26 2009-07-09 Newell Rogers M Karen Methods of modulating immune function
KR20090118993A (ko) * 2007-03-01 2009-11-18 심포젠 에이/에스 동족체 항체 클로닝 방법
EP2242836B1 (de) * 2008-01-28 2015-05-20 Thomas Jefferson University Verfahren zur herstellung von hybridzellen zur expression nützlicher antikörper
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
HUE028582T2 (en) 2008-11-28 2016-12-28 Univ Emory Method for determining the efficacy of PD-1 antagonists
WO2011000116A1 (en) * 2009-07-03 2011-01-06 Héma-Québec Use of steroidal compounds for the conversion of normal b lymphocytes into immunoglobulin-secreting plasma cells
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
US20130236905A1 (en) * 2010-05-18 2013-09-12 Christopher Marshall Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
ES2617488T3 (es) * 2011-11-23 2017-06-19 F. Hoffmann-La Roche Ag Células de mamífero que expresan CD40L y su uso
US9175072B2 (en) 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
EP3099709B1 (de) 2014-01-31 2019-12-25 AIMM Therapeutics B.V. Mittel und verfahren zur herstellung von stabilen antikörpern
US10166288B2 (en) * 2014-10-01 2019-01-01 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
KR101889327B1 (ko) * 2014-12-31 2018-09-20 (주)아모레퍼시픽 다양한 유화 입자 사이즈를 함유하는 혼성 유화 조성물 및 그 제조방법
US11236152B2 (en) 2015-11-03 2022-02-01 The United States of America, as represented by the Sectetary, Department of Health and Human Services Neutralizing antibodies to HIV-1 GP41 and their use
US11781112B2 (en) * 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
CN109563482A (zh) 2016-06-10 2019-04-02 埃尔瓦有限公司 含表达异于分泌免疫球蛋白和细胞溶解功能的膜免疫球蛋白的b淋巴细胞系的组合物和方法
KR102539610B1 (ko) * 2020-01-22 2023-06-02 한국생명공학연구원 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용
WO2024046305A1 (zh) * 2022-08-29 2024-03-07 江苏恒瑞医药股份有限公司 免疫调节剂的筛选和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
WO1999061617A1 (en) 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukins-21 and 22
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000078348A1 (en) * 1999-06-17 2000-12-28 University Of Vermont And State Agricultural College Autologous adoptive immunotherapy with primed antigen-specific t cells or b cells
WO2001077171A2 (en) 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
US20030013390A1 (en) * 2001-07-16 2003-01-16 Sheng Cheng Li Electrical knife sharpening device
DK1432431T3 (en) 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
US6929932B2 (en) 2001-11-05 2005-08-16 Zymogenetics, Inc. IL-21 antagonists
EP2141228A1 (de) * 2001-12-18 2010-01-06 Cancer Research Technology Limited Methode zur Herstellung von proliferierenden und differenzierenden B-Zelllinien
US20050063947A1 (en) 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
GB2422845B (en) 2003-11-19 2007-08-01 Us Gov Health & Human Serv Method of inducing memory B cell development and terminal differentiation

Also Published As

Publication number Publication date
DE602004028280D1 (de) 2010-09-02
US7993919B2 (en) 2011-08-09
US20080305076A1 (en) 2008-12-11
US20060057123A1 (en) 2006-03-16
EP1692276B1 (de) 2010-07-21
WO2005052139A2 (en) 2005-06-09
EP1692276A2 (de) 2006-08-23
DK1692276T3 (da) 2010-11-01
US8247228B2 (en) 2012-08-21
GB0609952D0 (en) 2006-06-28
WO2005052139A3 (en) 2005-09-22
GB2422845B (en) 2007-08-01
US20070003515A1 (en) 2007-01-04
GB2422845A (en) 2006-08-09
US7378276B2 (en) 2008-05-27

Similar Documents

Publication Publication Date Title
ATE474915T1 (de) Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen
ATE224457T1 (de) Verfahren zur identifizierung von nukleinsäuren, welche agenzien kodieren, die zelluläre phenotypen beeinflussen
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK1280898T3 (da) Modificerede ES-celler og ES-cellespecifikt gen
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
ATE416376T1 (de) Analysegeräte, biosensoren und verfahren
DE60223644D1 (de) Feststoffbrenner, Verfahren zur Verwendung desselben, Brennkessel und Verfahren für dessen Betrieb
BR0116109A (pt) Processo e aparelho para isolamento de espécies iÈnicas de um lìquido
ATE397752T1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
DE60234022D1 (de) Verfahren und vorrichtungen zur elektrophorese von vorgegossenen, hydratisierbaren trennmedien
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
NO20054947L (no) Statisk diffusjonscelle for diffusjonsprovetakingssystem
DE602004032000D1 (de) Festpolymerelektrolyt-Brennstoffzellensystem und Betriebsverfahren dafür
GB0322724D0 (en) A method of determining the identity of an unknown neighbour cell,and apparatus therefor
DE60334499D1 (de) Verfahren zur erhöhung der ausbreitung von b-zellen
ATE406461T1 (de) Rna-bioassay
ATE520770T1 (de) Humane eierstockmesothelialzellen und verfahren zu deren isolierung und verwendung
DK1185873T3 (da) Reportermolekyler og fremgangsmåde til analyse af höjspecifitetsproteaseraktivitet
BRPI0311182A2 (pt) método para isolar uma célula endotelial e método para realizar provas cruzadas específicas para o doador
DE60115039D1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität
DE602005005663D1 (de) Verfahren zur charakterisierung von verbindungen
BRPI0517700A (pt) células tronco, método para sua purificação, identificação e uso
HK1083534A1 (en) Method for identifying substances
ATE325889T1 (de) Screening-verfahren
WO2003104478A3 (en) DETECTION OF RNA STRUCTURAL ELEMENTS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties